How do anti-amyloid antibodies like lecanemab and donanemab work for Alzheimer's, and why are doctors cautious about ARI

Anti-amyloid antibodies are a class of medications designed to change the progression of Alzheimer’s disease by targeting the underlying pathology rather than just managing symptoms.

How they work

In the brains of people with Alzheimer’s, a protein called amyloid-beta clumps together to form plaques. These plaques are thought to disrupt cell function and trigger inflammation, leading to the cognitive decline associated with the disease.

• Mechanism: Both lecanemab and donanemab are monoclonal antibodies. When infused into the bloodstream, they act as "tags" for the immune system. They bind specifically to amyloid-beta plaques in the brain.
• Clearance: Once bound, these antibodies signal the brain's own immune cells—microglia—to identify, engulf, and clear away the amyloid deposits. By reducing the total "burden" of these plaques, these drugs aim to slow the rate of clinical decline in patients with early-stage Alzheimer’s.

Why doctors are cautious about ARIA

The primary safety concern associated with these treatments is ARIA, which stands for Amyloid-Related Imaging Abnormalities. Because the medications actively clear plaque from blood vessel walls in the brain, they can cause changes in vascular permeability.

There are two main types of ARIA, both of which are detected via MRI:

1. ARIA-E (Edema): This refers to swelling in the brain caused by fluid leaking from blood vessels. While many patients are asymptomatic, others may experience headaches, confusion, dizziness, or nausea.
2. ARIA-H (Hemorrhage): This refers to small spots of bleeding (microhemorrhages) or hemosiderin deposits (iron-containing pigment left over from past bleeding) in or around the brain.

Why the caution?

• Severity: Most cases of ARIA are mild and resolve on their own, but they can be serious and, in rare instances, life-threatening.
• Monitoring: Because patients are often unaware they are experiencing ARIA, doctors must perform regular, scheduled MRI scans to "catch" these changes before they become symptomatic.
• Genetic Factors: Patients who carry the APOE-ε4 gene—a known risk factor for Alzheimer’s—have a significantly higher risk of developing ARIA when treated with these drugs. Doctors often recommend genetic testing or careful counseling for these individuals.
• Stopping Treatment: If an MRI shows significant ARIA, the physician must typically pause or discontinue the medication to allow the brain tissue to heal.

Because of these risks, these treatments are administered in clinical settings with strict protocols, requiring patients to be closely monitored by a specialized medical team throughout the course of their therapy.